An antibody–drug conjugate active against antibiotic-resistant Neisseria gonorrhoeae
Proceedings of the National Academy of Sciences · 04.08.2026 · 123 (31)
DOI: 10.1073/pnas.2534217123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 28.07.2026. Verfasst von Hayley Lavender und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Immunoconjugates, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust (WT), ¿¿¿¿ | John Fell Fund, University of Oxford (John Fell OUP Research Fund), Rosetrees Trust (Rosetrees).
Abstract (Originalsprache)
Neisseria gonorrhoeae is the causative agent of gonorrhea, a sexually transmitted infection which is rising in incidence, with increasing drug-resistant strains posing a significant public health threat. To address the urgent need for novel therapies, we developed an antibody–drug conjugate (ADC) that targets this important human pathogen. We utilized Tridecaptin A 1, a potent antimicrobial peptide (AMP) against Gram-negative bacteria that exhibits significant toxicity against human cells, limiting its development for clinical use. By conjugating the Tridecaptin A 1 analogue, Oct-TriA 1 to a monoclonal antibody (mAb) that specifically targets gonococcal MtrE, the outer membrane component of a drug efflux pump that is upregulated in resistant strains, we aim to selectively deliver the AMP to the gonococcus. However, Oct-TriA 1 was not bactericidal when directly conjugated to mAb. To circumvent this, we exploited an immune evasion mechanism employed by the gonococcus by introducing a linker between Oct-TriA 1 and the mAb which is specifically cleaved by the IgA protease (IgAP) secreted by the gonococcus; the IgAP inactivates human IgA. This ADC has no detectable toxicity for relevant human cells, kills the gonococcus in an MtrE- and IgAP-dependent manner, and is active against a strain which is resistant to first line agents. This modular ADC platform could be extended to other bacterial pathogens which employ proteases to evade immune killing, offering a strategy in the fight against antimicrobial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom.
- The Department of Clinical Infection, Microbiology, and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 7BE, United Kingdom.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817.
- Department of Chemistry, University of Oxford, Oxford OX1 3TA, United Kingdom.
- School of Chemistry, University of Birmingham, Birmingham B15 2TT, United Kingdom.
- Department of Microbiology and Immunology, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814.
ORCID-Profile: Hayley Lavender, Vincent Oliver, Ann E Jerse, Christoph M Tang
Förderung
- Wellcome Trust (WT)
- ¿¿¿¿ | John Fell Fund, University of Oxford (John Fell OUP Research Fund)
- Rosetrees Trust (Rosetrees)
Zitieren
APA
Lavender, H., Oliver, V., Lucy, D., Barendt, T. A., Jerse, A. E., & Tang, C. M. (2026). An antibody–drug conjugate active against antibiotic-resistant Neisseria gonorrhoeae. Proceedings of the National Academy of Sciences, 123(31). https://doi.org/10.1073/pnas.2534217123
Vancouver
Lavender H, Oliver V, Lucy D, Barendt TA, Jerse AE, Tang CM. An antibody–drug conjugate active against antibiotic-resistant Neisseria gonorrhoeae. Proceedings of the National Academy of Sciences. 2026;123(31). doi:10.1073/pnas.2534217123
BibTeX
@article{Lavender2026,
author = {Lavender, Hayley and Oliver, Vincent and Lucy, Daniel and Barendt, Timothy A and Jerse, Ann E and Tang, Christoph M},
title = {An antibody–drug conjugate active against antibiotic-resistant Neisseria gonorrhoeae},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {31},
doi = {10.1073/pnas.2534217123}
}
EUVIMED